Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7:S1529-9430(25)00329-8.
doi: 10.1016/j.spinee.2025.07.010. Online ahead of print.

Association between glucagon-like peptide-1 receptor agonists and non-fusion risk after single-level anterior cervical discectomy and fusion

Affiliations

Association between glucagon-like peptide-1 receptor agonists and non-fusion risk after single-level anterior cervical discectomy and fusion

Yu Chang et al. Spine J. .

Abstract

Background: Anterior cervical discectomy and fusion (ACDF) is a common procedure for treating degenerative cervical spine diseases. Successful fusion is essential for spinal stability, while pseudarthrosis can lead to pain and revision surgery. Glucagon-like peptide-1 (GLP-1) drugs, used for type 2 diabetes (T2DM) and obesity, have demonstrated benefits in vascular and bone health.

Purpose: This study investigates whether perioperative GLP-1 drug use affects fusion rates in T2DM patients undergoing single-level ACDF.

Design: Retrospective cohort study PATIENT SAMPLE: T2DM patients undergoing single-level ACDF.

Outcome measurement: Risk of pseudarthrosis, identified using ICD-10 code M96.0, at 6 months, 1 year, and 2 years postoperatively.

Methods: A retrospective analysis was conducted using the TriNetX database, identifying T2DM patients who underwent single-level ACDF via CPT codes. Patients were categorized based on GLP-1 drug use within 6 months before or after surgery. A 1:1 propensity score matching (PSM) controlled for age, sex, race, and comorbidities.

Results: Before propensity score matching (PSM), 1,245 GLP-1 drug users and 13,519 non-users were included. After matching, 1,242 patients remained in each group. At 6 months, the non-fusion rate was 7.9% in the GLP-1 drug group and 13.6% in the non-user group (OR=0.55, 95% CI: 0.42-0.72, p<.001), indicating 45% lower odds of pseudarthrosis in GLP-1 drug users. This trend remained consistent at 1 year (8.8% vs. 14.5%, OR=0.57, 95% CI: 0.44-0.74, p<.001) and 2 years postoperatively (10.0% vs. 15.5%, OR=0.61, 95% CI: 0.48-0.78, p<.001), suggesting a sustained reduction in the risk of non-fusion with GLP-1 drug use.

Conclusions: Perioperative GLP-1 drug use is associated with a lower risk of pseudarthrosis in T2DM patients undergoing ACDF. These findings suggest a potential role for GLP-1 drugs in improving spinal fusion outcomes.

Keywords: Anterior cervical discectomy and fusion; Cervical spine surgery; Glucagon-like peptide-1 receptor agonists; Non-fusion; Pseudoarthrosis; Type 2 Diabetes Mellitus.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors declare no conflict of interests.

Similar articles

LinkOut - more resources